Abstract
Introduction: Exenatide once weekly (EQW) is an injectable glucagon-like peptide-1 receptor agonist that is pending approval at present by regulatory authorities for treatment of type 2 diabetes mellitus. Its glucose-reducing and weight-loss properties, together with minimal hypoglycemia and a once-weekly dosing schedule, make it a potentially attractive treatment option for overweight type 2 diabetics.Areas covered: A literature search using PubMed resulted in a search for all published clinical trials with EQW, entitled the DURATION trials, which are reviewed in this paper. Efficacy and safety data are compared with other available antidiabetes agents. Molecular structure, pharmacokinetics, pharmacodynamics and mechanism of action are also reviewed.Expert opinion: EQW is a potentially attractive medication for overweight type 2 diabetics with efficacy in both glycemic control and weight loss, as well as minimal hypoglycemia. Owing to its route of administration and expected cost compared with generic metformin, it will probably have a role as add-on therapy rather than monotherapy. Additional studies are ongoing to compare its efficacy against liraglutide.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
